Cryoport (CYRX) Authorizes $100 Million Repurchase Program

Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has unanimously authorized a repurchase program, under which Cryoport may repurchase up to $100 million of its outstanding common stock and/or convertible senior notes.

Jerrell Shelton, Cryoport CEO, said, "The authorization of the repurchase program reflects our constant focus on shareholder return and effective capital allocation. The authorization of this repurchase program demonstrates the Board's confidence in our business model and outlook, our financial performance, and our commitment to delivering value to our stakeholders. We plan to opportunistically repurchase shares of our common stock and convertible senior notes, while maintaining ample liquidity to support our growth organically and through potential acquisitions."

Repurchases may be made from time to time on the open market or otherwise, in such quantities, at such prices, and in such manner as determined by management at its discretion and will depend on a number of factors, including the market price of Cryoport's common stock, general market and economic conditions, and applicable legal requirements. The repurchase program will expire on December 31, 2025 and may be extended, suspended, modified or discontinued at any time. The company does not expect to incur debt to fund the repurchase program.

Upcoming Investor Conferences

Cryoport will be presenting at the following upcoming investor conferences:

• Roth 34th Annual - March - 13th-15th - California
• KeyBanc Life Sciences & MedTech – March – 22nd – 23rd - Virtual
• Needham Healthcare – April 11th-14th - Virtual
• B Riley 22nd Institutional Investor – May 25th-26th - California
• UBS Global Healthcare – May 23rd-25th - New York
• Jefferies Global Healthcare – June 8th-10th – New York

You May Also Be Interested In